News
Press ReleaseRevive Therapeutics Announces $10 Million Bought Deal Offering of Units
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”
Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.
Dr. Moody stated: “I look forward to serving as a medical and clinical advisor to Revive for both their FDA Phase 3 study and their expansion initiatives in Canada for clinical studies in COVID-19.”